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Abstract
Background: There has been a global increase in the use of herbal medicinal products (HMPs). About a quarter of
UK adults use HMPs, bought over the counter by self-prescription and often not disclosed to healthcare professionals.
Potential herb-drug interaction is a clinical concern, with older people at greater risk because of co-morbidities and
slower clearance of pharmacologically active compounds. While there is a good understanding of general herbal
medicine use by older people, less is known about the extent and implications of concurrent use with prescription
medicines. The aim of this systematic review is to assess the prevalence, patterns, safety issues and other factors
associated with concurrent prescription and herbal medicines use among older adults.
Methods/design: Systematic electronic searches of MEDLINE, PsychINFO, Excerpta Medica dataBASE (EMBASE),
Cumulative Index to Nursing and Allied Health Literature (CINAHL), Allied and Complementary Medicine Database
(AMED), Web of Science and Cochrane from inception till present for studies reporting the concurrent use of
prescription medicines with HMPs in older adults (≥65 years). Lateral searching via related citation (PubMed) and
checking reference lists of identified studies will be performed. Two reviewers will independently screen studies, extract
data and appraise methodological quality using the Joanna Briggs Institute checklist for prevalence data and the
Critical Appraisal Skills Programme (CASP) checklist. Qualitative and quantitative studies from all settings will be
included. Non-empirical papers, in vitro experiments and animal studies will be excluded. Primary outcomes are
prevalence and patterns of concurrent use, number and types of prescription and HMPs and adverse reactions
reported. Secondary outcomes are disclosure of HMP use to healthcare professionals and cost of HMPs. A narrative
synthesis of included studies will be performed to summarise the evidence.
Discussion: This review will synthesise and critically appraise current knowledge on the concurrent use of drugs and
HMPs by older adults and thus provide a better understanding of the issue. It will also identify any gaps in knowledge.
By establishing safety issues associated with concurrent use, it will also inform strategies that can help practitioners to
identify and manage older people at potential risk of herb-drug interactions.
Systematic review registration: PROSPERO CRD42014009091
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Background
The last two decades have witnessed a global increase in
the use of herbal medicinal products (HMPs) [1]. Herbal
medicinal product is described as “any medicinal product,
exclusively containing as active ingredients one or more
herbal substances or one or more herbal preparations, or
one or more such herbal substances in combination with
one or more such herbal preparations” [2]. High preva-
lence of HMPs use has been reported in the UK [3–5].
Herbal medicinal products are bought over the counter,
mostly self-prescribed [5–7] and often not disclosed to
healthcare professionals [8, 9]. Reasons for the increasing
use of HMPs include dissatisfaction with the effectiveness
of conventional drugs, concerns about adverse effects of
conventional drugs and misconception that HMPs are
‘natural’ and therefore safer, even when or particularly
when used with prescription drugs [7]. Other reasons for
the increased use of HMPs include desire to contribute to
the treatment process and to improve general health, cul-
tural and personal beliefs and better consultation experi-
ences with herbal medicine practitioners when compared
to conventional healthcare professionals [10].
Interactions between conventional drugs and HMPs
can lead to adverse drug reactions (ADR), some with ser-
ious consequences [11–14]. For example, ginkgo (Ginkgo
biloba) when combined with anticoagulants can interfere
with platelet functions. Although the majority of drug-
drug interactions are known and preventable, little is
known about the incidence and severity of HMP-drug in-
teractions. The risk for ADRs increases with age [14, 15].
Considering that 16 % of the population of England and
Wales are 65 years and older, this is an issue that needs
closer attention [16]. Older people are more likely to live
with multiple co-morbidities and experience medication-
related problems because of delayed clearance of pharma-
cologically active compounds [17–19]. Twenty per cent of
over 70s take five or more prescribed medications [20, 21];
the number of medications increases the risk of an adverse
drug event [22, 23]. Increased hospitalisation and pro-
longed hospital stays due to ADRs are also major clinical
and economic concerns for all healthcare systems [24].
While there is a considerable body of knowledge on the
use of herbal medicines by different age groups and for
different conditions, there is limited evidence on the con-
current use of herbals with conventional medicines espe-
cially among older adults [25]. We define concurrent use
as taking one or more HMPs in the same time period with
a prescription medicine.
Aims
This systematic review aims to identify and synthesise
the literature on prevalence, patterns, safety issues and
other factors associated with concurrent prescription
and HMP use in older adults.
Review questions
The review will seek to answer the following questions:
a. What is the prevalence and pattern of the
concurrent use of prescription drugs and herbal
medicinal products (HMPs) among older adults?
b. What patient and clinical characteristics are
associated with the concurrent use of prescription
drugs and HMPs?
c. What are the range of prescription drugs and HMPs
most concurrently used by older adults?
d. What safety issues and other factors are associated
with concurrent prescription drug and HMPs use in
older adults?
Methods/design
Protocol and registration
The methods for this systematic review were developed
according to recommendations from the Preferred Re-
porting Items for Systematic Reviews and Meta-Analyses
Protocols (PRISMA-P) statement [26]. A populated
PRISMA-P checklist is available as an Additional file 1 to
this protocol. The protocol has been registered in the
International Prospective Register of Systematic Reviews:
PROSPERO 2014: CRD42014009091.
Eligibility criteria
We will include studies with participants who are ≥65 years,
studies with a mean participant age of ≥65 years and
studies from which standalone data for ≥65 years can be
extracted. We will include studies assessing the concur-
rent use of HMPs or herbal dietary supplements with
prescription medicines. Studies in which participants
were on at least one prescription medicine and concur-
rently used one or more HMP will also be eligible.
Type of studies
We will include the following study designs:
a. Quantitative study design: quantitative studies which
may include cross-sectional studies to answer review
questions on prevalence, pattern of use, range of
prescription and HMPs and patient and clinical
characteristics associated with concurrent use
among older adults
b. Qualitative study design: qualitative studies on
satisfaction or dissatisfaction with HMPs and
disclosure to healthcare professionals, as well as
cost and resources expended on HMPs by older
adults
c. Mixed method studies: studies which have
incorporated both quantitative and qualitative
strands in their design
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d. Case reports of adverse events from the concurrent
use of prescription drugs and HMPs among those
aged 65 years and older
Studies assessing Chinese herbal medicine, Ayurvedia,
Kampo, Siddha, Unani, homoeopathic remedies, non-
herbal dietary supplements and vitamins will be ex-
cluded as they often contain products other than plants.
Combination products, i.e. products that contain herbal
as well as non-herbal (vitamins, minerals) ingredients
will be excluded. Editorials, letters, commentaries and
papers reporting in vitro experiments and animal studies
will be excluded.
The primary outcomes of interest include prevalence
and pattern of concurrent use, names and number of
concurrently used medicines, adverse reactions or po-
tential herb-drug interactions reported. Secondary out-
comes of interests are the disclosure of HMPs use to
healthcare professionals, satisfaction with HMPs and
cost of HMPs, where reported.
Literature searches
We will search the following databases from inception
to November 2015 using medical subject headings
(MeSH) and text words related to ‘herbal medicine’, ‘pre-
scription drugs’ and the scientific name and common
names(s) of herbs most documented for concomitant
use. Cumulative Index to Nursing and Allied Health
Literature (CINAHL) via EBSCO, Cochrane Library,
Excerpta Medica dataBASE (EMBASE), MEDLINE (via
PubMed), the Allied and Complementary Medicine
Database (AMED), PsychINFO, Web of Science and
Google Scholar. No restrictions will be placed on lan-
guage of publication. The search strategy is available as
an Additional file 2 to this protocol.
We will also search reference lists of all identified
studies and review articles for relevant references not
identified by the electronic search. Key authors and ex-
perts in the field identified from reference list of in-
cluded studies will be contacted for information about
ongoing or unpublished studies. Duplicate studies will
be recorded and discarded. We will also perform lateral
searching using the related citation function in PubMed
and cited by function in Google scholar to capture all
relevant articles.
Study selection process
Search results from all databases will be downloaded
into Endnote and merged to remove duplicates. Two
reviewers (Taofikat Agbabiaka (TA) and Barbara Wider
(BW)) will scan all titles and abstracts for potential
relevance. Any article for which there is uncertainty
about relevance will be retained and the full text
reviewed. Full text of all articles that may meet the
eligibility criteria will be obtained and downloaded into
Endnote.
Using a pre-designed eligibility checklist, two reviewers
(TA and BW) will independently assess the full text of all
obtained articles against the eligibility criteria and an eligi-
bility code will be recorded. Studies that do not meet the
inclusion criteria will be excluded and the reasons re-
corded. Any disagreements on eligibility will be resolved
by discussion between two reviewers (TA and BW); if
no consensus can be reached, a third reviewer (Claire
Goodman (CG)) will be consulted.
Data extraction
Using a piloted data extraction form, one reviewer (TA)
will extract the data from included studies and a second
reviewer (BW) will validate the extracted data. Key data
to be extracted will include the following:
a. Publication details: author (s), year of publication,
title of paper, journal and country in which study
was conducted and funding information
b. Study design: study type, recruitment method and
data collection method(s)
c. Study aims, outcomes and measurement of
outcomes.
d. Participants: demographic and socio-economic
characteristics, number surveyed, or interviewed and
previous medical diagnosis
e. Name/description and number of HMPs and name
and number of prescription drug(s)
f. Details of safety issues: adverse reactions and
interactions reported
g. Disclosure, satisfaction and cost/resource
h. Study limitations: response bias, selection bias, etc.
Any disagreements will be resolved by a third reviewer
(CG) or by achieving a consensus through discussion.
Studies that do not meet the inclusion criteria will be ex-
cluded and the reasons recorded.
Quality assessment
Two reviewers (TA and BW) will independently assess
the methodological quality of each article that meets the
inclusion criteria. Where appropriate, studies assessing
prevalence will be assessed using the Joanna Briggs In-
stitute (JBI) checklist for prevalence data [27]. Qualita-
tive papers will be assessed for methodological rigour
using the checklist developed by Critical Appraisal Skills
Programme (CASP) [28].
Data synthesis
We will adopt the EPPI-Centre three stages approach to
mixed method research synthesis [29]. A first synthesis
will aim to address prevalence, pattern of use and
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patient characteristics associated with the concurrent
use of herbal medicinal products and prescription medi-
cines. A second synthesis of qualitative research will ad-
dress the fourth review question, i.e. safety issues and
other factors such as disclosure, satisfaction and cost/re-
sources. We do not anticipate many qualitative research
papers; therefore, synthesis will depend on available data.
We will use thematic synthesis to identify key themes,
commonalities, and why HMPs are thought to be helpful
or necessary [30]. Findings from both quantitative and
qualitative stages will be summarised in a narrative ac-
count that addresses the review questions to provide
a better understanding of concurrent medicine use
among older adults.
Results of the search and study selection process will
be presented in a flow chart [31]. Relevant data ex-
tracted from eligible studies will be presented as an
evidence table. We will describe the study characteris-
tics including details of study types, population charac-
teristics and outcomes. We will provide a narrative
synthesis of the summary of prevalence, patterns and
safety issues from concurrent prescription and HMPs
use in older adults. Where appropriate we will present
data in tables and graphics. We will provide a detailed
discussion of the limitations of the included studies
and their implications on the findings. We will identify
gaps in knowledge and provide suggestions for future
research.
Discussion
Failure to review and manage the concurrent use of pre-
scription and herbal medicines in older adults is a con-
siderable patient safety risk. Excessive and inappropriate
medicine use is common among older adults [32, 33],
and concurrent use with HMPs further complicates the
problem.
This review is a significant addition to knowledge due
to the paucity of evidence on the concurrent use of pre-
scription drugs and HMPs in older adults. There is no
up-to-date review on concurrent prescription and herbal
medicine use among UK older adults; the only previous
related study [34] is over a decade old. The review will
provide healthcare professionals with up-to-date know-
ledge on the prevalence and factors associated with con-
current medication use among this population. It will
also provide important baseline information for future
intervention research.
Dissemination
Findings from this systematic review will form part of
TA’s doctoral thesis. The review will be prepared fol-
lowing PRISMA reporting standards for submission to
a peer-reviewed journal with focus on care of older
adults or drug safety and presented at conferences.
Additional files
Additional file 1: Preferred Reporting Items for Systematic Review and
Meta-Analysis Protocols (PRISMA-P) is an evidence-based minimum set of
items for reporting in protocols of systematic reviews and meta-analyses.
Additional file 2: Search strategy used for Medline detailing keywords,
subject headings, search terms, search techniques and combination of
search terms.
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